Merck MRK announced that the FDA has granted the Breakthrough Therapy designation (BTD) to its B7-H3-directed DXd ...

Pfizer is advancing research and building a comprehensive "toolbox" for Vietnamese patients, combining innovative vaccines, ...

However, that number is skewed due to Pfizer's year-end results. In the last three months of 2024, the company incurred ...

Architect Levitt Bernstein, in collaboration with low energy specialist Etude, has developed a three-part document package for Greater Manchester Combined Authority, to help applicants comply with the ...

Pfizer’s investigational drug for sickle cell disease failed in a critical Phase III trial. The company announced that the ...

O’Reilly Auto Parts will become the title sponsor for NASCAR’s second-tier national series when the Xfinity Series is renamed ...

NEW YORK, NY, USA I August 15, 2025 I Pfizer Inc. (NYSE: PFE) today announced results from the Phase 3 THRIVE-131 study evaluating inclacumab, an ...

Pfizer (NYSE: PFE) reported that its Phase III THRIVE-131 study of inclacumab, an experimental P-selectin inhibitor for ...

Pfizer Inc. just got a price target bump from Citi. Following a robust Q2, Citi upgraded Pfizer's price target from $25 to ...

With strong hedge fund interest and a low price-to-earnings ratio, Pfizer Inc. (NYSE:PFE) secures a place on our list of the ...

Pfizer beats Q2 estimates with $14.7B revenue and $0.78 EPS. Management showed extreme confidence by raising full-year EPS ...

Pfizer's Phase 3 trial of inclacumab in sickle cell disease misses its main goal but shows safety, with further updates on other drugs planned.